title: Benoxaprofen: once a day vs twice a day in patients with rheumatoid arthritis or osteoarthritis.
abstract: This multicenter clinical trial was conducted in patients with rheumatoid arthritis and osteoarthritis in an effort to evaluate and compare the efficacy and safety of benoxaprofen when taken as a single 600 mg dose in the evening or when taken in 2 300 mg doses. The results of the double-blind crossover studies demonstrated the effectiveness of the qd and bid dose and revealed no significant difference between the 2 dose regimens. They also showed the once-daily dose, a dose that is more convenient and easier to comply with, to be as effective as the twice-daily dose.
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001583:Benzoxazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D010349:Patient Compliance; D011422:Propionates / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D001583:Benzoxazoles; D011422:Propionates; C011677:benoxaprofen